Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Invitrogen IVGN -- Ignore unavailable to you. Want to Upgrade?

To: mopgcw who wrote (30)	12/16/2005 2:33:41 AM
From: mopgcw	Respond to of 73

UPDATE 1-Invitrogen projects 2005, 2006 earnings per share Wed Dec 14, 2005 09:02 PM ET (Adds analyst estimates) LOS ANGELES, Dec 14 (Reuters) - Invitrogen Corp. (IVGN.O: Quote, Profile, Research) , a maker of tools and cultures used in drug development and production, said on Wednesday that it expects 2005 earnings per share to hit the "range of $3.42 plus", on sales of more than $1.19 billion. For 2006, the company projected pro forma earnings per share of $3.90 to $4.10. Wall Street analysts, on average, expect the company to earn $3.43 per share this year and $3.91 per share in 2006, according to Reuters Estimates.